{"entity":{"id":"ajai-chari","kind":"person","name":"Ajai Chari","aka":[],"tldr":"Led the pivotal talquetamab trial, establishing GPRC5D as the second bispecific target in myeloma.","summary":"Ajai Chari was principal investigator and first author of MonumenTAL-1, the trial that established the GPRC5DxCD3 bispecific talquetamab in relapsed myeloma and validated a target beyond BCMA. He has led studies of subcutaneous daratumumab, selinexor and real-world outcomes in myeloma and directs the myeloma programme at UCSF after many years at Mount Sinai.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chari%20A%5BAuthor%5D%20talquetamab"}],"tags":["myeloma","bispecific","gprc5d"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":["bispecific-antibody","t-cell-engager"],"targets":["gprc5d","cd3","cd38"],"drugs":[],"companies":[],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":["monumental-1"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director of the Multiple Myeloma Program, UCSF Helen Diller Family Comprehensive Cancer Center","institutionId":"ucsf","specialisms":["Multiple myeloma","Bispecific antibodies","GPRC5D-targeted therapy","Real-world outcomes"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chari%20A%5BAuthor%5D%20talquetamab"}],"papers":[{"title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma (MonumenTAL-1)","journal":"NEJM","year":2022,"doi":"10.1056/NEJMoa2204591"},{"title":"Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA)","journal":"Lancet Haematology","year":2020,"doi":"10.1016/S2352-3026(20)30070-3"}]},"route":"/people/ajai-chari/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"target":[{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"},{"id":"cd38","kind":"target","name":"CD38","route":"/targets/cd38/"},{"id":"gprc5d","kind":"target","name":"GPRC5D","route":"/targets/gprc5d/"}],"institution":[{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/"}],"trial":[{"id":"monumental-1","kind":"trial","name":"MonumenTAL-1","route":"/trials/monumental-1/"}]}}